Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson's Disease

被引:39
|
作者
Na, Sang J. [1 ,2 ]
DiLella, Anthony G. [1 ,2 ]
Lis, Edward V. [1 ,2 ]
Jones, Keith [1 ,2 ]
Levine, David M. [3 ]
Stone, David J. [3 ]
Hess, J. F. [1 ,2 ]
机构
[1] Merck Res Labs, Dept Stroke, West Point, PA 19486 USA
[2] Merck Res Labs, Dept Neurodegenerat, West Point, PA 19486 USA
[3] Rosetta Inpharmat LLC, Seattle, WA USA
关键词
6-OHDA; 6-Hydroxydopamine; Dopaminergic; CED; Convection-enhanced delivery; Parkinson's; Substantia nigra; Striatum; Microarray; Gene expression; Taqman; HYDROXYLASE MESSENGER-RNAS; SUBSTANTIA-NIGRA; DOPAMINE NEURONS; GENE-EXPRESSION; INTRASTRIATAL; 6-HYDROXYDOPAMINE; INSITU HYBRIDIZATION; OXIDATIVE STRESS; CDNA MICROARRAY; RAT STRIATUM; CELL-DEATH;
D O I
10.1007/s11064-010-0133-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Convection enhanced delivery of 6-hydroxydopamine (6-OHDA) to the rat striatum results in a model of Parkinson's disease. An important feature of this unilateral model is the progressive loss of dopaminergic (DA) neurons over the course of several weeks. To improve the understanding of this model, gene expression changes in the substantia nigra, which contains the DA neuron cell bodies, and the striatum, which contains the DA neuron synaptic terminals, were examined using DNA microarrays. Samples were collected and behavior was analyzed from vehicle and toxin treated animals at 3 days, 1 week, 2 weeks and 4 weeks following 6-OHDA treatment. Tissue DA content was determined and samples from animals which exhibited a substantial depletion of striatal DA were included in the subsequent gene expression analysis. The results of the gene expression analysis indicated that 6-OHDA elicits a vigorous inflammatory response, comprised of several distinct pathways, in the striatum at the earliest time point tested. In contrast, relatively few gene expression changes were observed in the SN at the 3-day time point. In both tissues examined there was evidence for a vigorous inflammatory response at the 1- and 2-week time points, which was substantially diminished by the 4-week time point. Inflammation plays a prominent role in the 6-OHDA model of Parkinson's disease.
引用
收藏
页码:761 / 772
页数:12
相关论文
共 50 条
  • [1] Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson’s Disease
    Sang J. Na
    Anthony G. DiLella
    Edward V. Lis
    Keith Jones
    David M. Levine
    David J. Stone
    J. F. Hess
    Neurochemical Research, 2010, 35 : 761 - 772
  • [2] The 6-hydroxydopamine model of Parkinson's disease
    Simola, Nicola
    Morelli, Micaela
    Carta, Anna R.
    NEUROTOXICITY RESEARCH, 2007, 11 (3-4) : 151 - 167
  • [3] The 6-Hydroxydopamine model of parkinson’s disease
    Nicola Simola
    Micaela Morelli
    Anna R. Carta
    Neurotoxicity Research, 2007, 11 : 151 - 167
  • [4] The 6-hydroxydopamine Rat Model of Parkinson's Disease
    Guimaraes, Rayanne Poletti
    Ribeiro, Danilo Leandro
    dos Santos, Keila Bariotto
    Godoy, Livea Dornela
    Correa, Mirella Rosine
    Padovan-Neto, Fernando Eduardo
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (176):
  • [5] Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease
    Sadeghian, M.
    Mullali, G.
    Pocock, J. M.
    Piers, T.
    Roach, A.
    Smith, K. J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2016, 42 (05) : 423 - 435
  • [6] Neuroprotection of edaravone in a 6-hydroxydopamine model of Parkinson's disease
    Li, G.
    Tian, J.
    MOVEMENT DISORDERS, 2006, 21 : S344 - S345
  • [7] Transcriptome profiling of five brain regions in a 6-hydroxydopamine rat model of Parkinson's disease
    Lyu, Ying
    Huang, Yiying
    Shi, Guiying
    Lei, Xuepei
    Li, Keya
    Zhou, Ran
    Bai, Lin
    Qin, Chuan
    CNS NEUROSCIENCE & THERAPEUTICS, 2021, 27 (11) : 1289 - 1299
  • [8] Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease
    Sharma, R
    McMillan, CR
    Tenn, CC
    Niles, LP
    BRAIN RESEARCH, 2006, 1068 (01) : 230 - 236
  • [9] Neuroprotective effect of pioglitazone in the 6-hydroxydopamine model of Parkinson's disease
    Machado, M. M. F.
    Bassani, T. B.
    Moura, E. L. R.
    Coppola-Segovia, V.
    Zanata, S.
    Vital, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S652 - S652
  • [10] Respiratory activity in the 6-hydroxydopamine model of Parkinson's disease in the rat
    Budzinska, Krystyna
    Andrzejewski, Kryspin
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2014, 74 (01) : 67 - 81